title: Development of fecal microbiota transplantation suitable for mainstream medicine.
abstract: Fecal microbiota transplantation has emerged as an increasingly common treatment for patients with refractory Clostridium difficile infection. Although it can be relatively simple to perform, a number of challenges need to be overcome before this procedure is widely accepted in mainstream clinical practice. Most of the solutions to these challenges already exist, but some need further optimization and testing. Standardized fecal microbiota is being developed as a therapeutic agent, although it clearly challenges some of the existing paradigms of drug development, delivery, and regulation.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Center for Immunology, University of Minnesota, Minneapolis, Minnesota; BioTechnology Institute, University of Minnesota, Minneapolis, Minnesota. Electronic address: khoru001@umn.edu.
authors.forename: Alexander
authors.initials: A
authors.lastname: Khoruts
authors.affiliation: BioTechnology Institute, University of Minnesota, Minneapolis, Minnesota; Department of Soil, Water, and Climate, Microbial and Plant Genomics Institute, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Sadowsky
authors.affiliation: BioTechnology Institute, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Hamilton
mesh_terms: D035843:Biomedical Research / Q000639:trends; D016360:Clostridioides difficile / Q000302:isolation & purification; D003015:Clostridium Infections / Q000382:microbiology / Q000628:therapy; D000069467:Fecal Microbiota Transplantation / Q000379:methods*; D005767:Gastrointestinal Diseases / Q000628:therapy*; D000069196:Gastrointestinal Microbiome; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans
keywords: Clostridium difficile infection; Fecal Transplant; Microbiome; Microbiota